Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II to III breast cancer.
The Phase 1 study evaluated MVP S in combination with letrozole, a commonly prescribed neoadjuvant hormone therapy, in postmenopausal patients prior to surgery. According to the company, the combination generated a strong immune response and meaningful biological activity across all treated participants. While the study enrolled only three patients, the consistency of the results is worth noting.
All three patients experienced at least a 50 percent reduction in Ki 67, a key biomarker used to measure tumor cell proliferation. Median Ki 67 levels declined from 24 percent at biopsy to 6 percent at surgery following treatment. One patient also demonstrated an eight fold increase in survivin specific interferon gamma T cells, a signal associated with enhanced immune mediated tumor response.
MVP S is built on BioVaxys proprietary DPX immune educating platform, which differs from traditional vaccine approaches by avoiding immediate antigen release at the injection site. Instead, the platform forces active uptake by immune cells and delivery to lymph nodes, promoting a sustained and targeted immune response. The therapy targets survivin, a cancer antigen commonly overexpressed in breast cancer and other solid tumors, and often associated with resistance to aromatase inhibitors such as letrozole.
The results address a well recognized challenge in hormone receptor positive, HER2 negative breast cancer. While neoadjuvant hormone therapy can reduce the need for chemotherapy and allow breast conserving surgery in roughly half of patients, responses vary widely and complete responses remain uncommon. HR positive, HER2 negative tumors represent the largest segment of the breast cancer market, accounting for more than half of total cases, with the broader HER2 negative market projected to exceed $21 billion by the end of the decade.
Management described the data as encouraging and indicated plans to further analyze systemic immune responses and tumor samples collected before and after treatment. That additional profiling is expected to support the design of a Phase 2 study aimed at modifying the tumor immune environment in higher risk patients.
While still early, the study reinforces the broader potential of BioVaxys platform across multiple oncology indications. MVP S is already being evaluated in later stage studies for other cancers, positioning this breast cancer data as an incremental validation of the company’s approach.
Shares of BIOV are up 9.1 percent at C$0.24 in Wednesday trading, while U.S. listed BVAXF shares are higher by about 9 percent at $0.18.
Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on AllPennyStocks.com.
About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: ads@allpennystocks.com
Phone: (800) 558-4560 Ext: 101
]]>